Global Phenylketonuria Market growing at a CAGR of 5.2% from 2023 to 2030
Category : Pharmaceuticals And Healthcare | Published Date : Aug 2023
Key Market Overview
Consegic Business Intelligence analyzes that the global phenylketonuria market is growing with a CAGR of 5.2% and is expected to reach USD 1,230.05 million in 2030 from USD 820.57 million in 2022.
The report highlights the increasing prevalence of phenylketonuria propelling the phenylketonuria market growth. Consegic Business Intelligence study also provides insights into the market's competitive landscape, market segmentation, regional outlook, and emerging technologies in the phenylketonuria market.
Global Phenylketonuria Market By Overview
The phenylketonuria market is bifurcated into type, product type, and distribution channel. Based on type, the market is segmented into hyperphenylalaninemia, mild PKU, moderate and variant, and classic PKU. In 2022, the classic PKU segment accounted for the highest market share in the phenylketonuria market. The product type segment is categorized into drugs (Kuvan, Pegavaliase, and others), nutritional supplements, and others. In 2022, the nutritional supplements segment accounted for the highest market share. On the basis of distribution channels, the market is segmented into hospital pharmacies, retail pharmacies, online pharmacies, and others. In 2022, the hospital pharmacies segment accounted for the highest market share in the overall phenylketonuria market.
Get Free SampleMarket Dynamics
Driver:
- Increasing prevalence of phenylketonuria is propelling the phenylketonuria market growth.
- Increased research and development in the field of genomics and bioinformatics is driving market growth.
Restraints:
- High cost of phenylketonuria treatments is restraining the market growth.
Opportunity:
- Increasing support and funding for research and development of new PKU treatments is likely to accelerate market growth.
Market Segmentation:
| Report Attributes | Report Details |
| By Type | Hyperphenylalaninemia, Mild PKU, Moderate and Variant, and Classic PKU |
| By Product Type | Drugs (Kuvan, Pegavaliase, and Others), Nutritional Supplements, and Others |
| By Distribution Channel | Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others |
| By Region | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Competitive Landscape :
The market is dominated by certain major companies such as Cambrooke Therapeutics., BioMarin Pharmaceutical, Inc., and PTC Therapeutics have a strong market position in current market circumstances. Further, the phenylketonuria market is expected to witness significant growth in the coming years due to the increasing support and funding for research and development of new PKU treatments. The market players compete for a firm market position through mergers and acquisitions, product innovations, and business strategies. Thus, evolving research and developments are expected to help market players adopt innovative ways of product creation to cater to the growing needs of various end-use industries.
- Cambrooke Therapeutics
- American Gene Technologies International, Inc.
- BioMarin Pharmaceutical, Inc.
- PTC Therapeutics
- Relief Therapeutics Holding SA
- Codexis, Inc.
- Agios Pharmaceuticals Inc
- Castle Crek Biosciences, Inc.
- Synlogic
- Pristine Organics
- Galen Pharma